General Discussion Topics, page-74710

First 74710 Last

Share
Profile

Follow
grafiksammler

702 Posts.

234

02/10/22

23:09

Post #: 63991276
Share
Originally posted by Eggboy: ↑

Just to engage once and only time on this long running topic.

"50% of production or 113,000 tonnes, whichever is greater."

Firstly, an important contextual obligation here is the term of the agreement or clause. Unless otherwise specified, the obligation above is for the term of the agreement. If somewhere it states that it is per annum (or some other term), then that would set the term to which this clause / obligation applies. (you all may / probably know this!!)

Secondly, the clause simply needs to be broken into its two key obligations:
The primary (first) obligation is "50% of production" (from NAL to PLL). This obligation is clearly that PLL get 50% of whatever is produced.
The secondary obligation is "or 113,000, whichever is greater". This obligation appears to be so PLL could secure a minimum production quantity (for whatever reason they had to want / require this), if it is that 50% of production falls below this figure

So, examples:
If SYA produce 100,000, then PLL get 100,000 tonnes, SYA 0.
If SYA produce 200,000 tonnes from NAL, PLL get access to 113,000 tonnes and SYA 87,000 tonnes.
If SYA produce 300,000 tonnes, PLL get 150,000 and SYA 150,000 tonnes.

However, (imo) there is no way to have a definitive interpretation.

The way the clause reads, by itself, is complicated by two things:
The framing of the phrase. IMO the phrase should have read (for clarity) - "50% of production or a minimum of 113,000 tonnes, whichever is greater." (This assumes my interpretation that PLL wanted a minimum quantity, is correct).
The other is contextual ambiguity. This arises due to the complete lack of context. To be definitive would require seeing he rest of the document in order to make meaning of this clause (sentence), as trying to definitely conclude what it means out of context is fraught with assumptions and difficulty.

EB

Expand

I don´t agree with your calculation bcause you didn´t include a timeframe.
50% or 113.000t on the LOM? Or till change to carbonate ends production of SC6? Or per year?

Where is written "at first"?

I interpret it, that at the end of a year (wether financial- or calender-year) SYAQ is commited to have delivered the the agreed tonnage

If you think PLL first, second SYAQ please be so kind and copy this agreement.
SYA Price at posting: 23.5¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 69,631 more messages in this thread...

First 74710 Last

Add SYA (ASX) to my watchlist

(20min delay)
Last 3.5¢		Change 0.004(12.9%)		Mkt cap ! $355.1M

Open	High	Low	Value	Volume
3.3¢	3.6¢	3.2¢	$1.977M	58.32M

Buyers (Bids)

No.	Vol.	Price($)
45	6583961	3.4¢

Sellers (Offers)

Price($)	Vol.	No.
3.5¢	3739852	26

View Market Depth

No.	Vol.	Price($)
44	6386246	0.034
30	8728453	0.033
30	8350279	0.032
20	9055871	0.031
32	4661630	0.030

Price($)	Vol.	No.
0.035	3704949	15
0.036	14928782	65
0.037	13080823	34
0.038	12452771	27
0.039	5078914	21

Last trade - 15.08pm 07/10/2024 (20 minute delay)

SYA (ASX) Chart

General Discussion Topics, page-74710

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

General Discussion Topics, page-74710

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News